<DOC>
	<DOCNO>NCT02881762</DOCNO>
	<brief_summary>This single-site , longitudinal , open-label , interventional study evaluate effect maraviroc hepatitis C viral level patient infect hepatitis C human immunodeficiency virus ( HIV ) take antiretroviral therapy HIV .</brief_summary>
	<brief_title>Maraviroc Efficacy Hepatitis C</brief_title>
	<detailed_description>Recently , in-vitro study ( experiment perform laboratory , person ) demonstrate maraviroc , medication use human immunodeficiency ( HIV ) therapy , appear significant hepatitis C antiviral effect , comparable sofosbuvir-a potent anti-hepatitis C medication . In study , investigator evaluate antiviral effect maraviroc hepatitis C virus people infect hepatitis C HIV , never treat hepatitis direct antiviral agent . Participants take maraviroc 4 week addition regular HIV antiretrovirals ( ART ) . The investigator measure hepatitis C viral load , , 4-week maraviroc time .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>1 . 18 year old 2 . Hepatitis Cinfected without plan undergo hepatitis C treatment duration study 3 . Human immunodeficiency virus ( HIV ) infect 4 . Currently receive antiretroviral therapy HIV viral load &lt; 50 IU/ml ≥ 12 month . One virologic blip ≤ 400 copies/ml permissible within 12 month 5 . CD4 T cell count &gt; 100 cells/mm3 6 . Noncirrhotics cirrhotics include 7 . Willing sign inform consent 1 . Age &lt; 18 2 . Unable comply study visit , research study visit , plan relocate study . 3 . Have condition investigator considers contraindication study participation 4 . Pregnancy breast feed 5 . Decompensated liver disease ( ChildPugh C ) 6 . Imminent treatment hepatitis C infection 7 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal 8 . Concomitant use drug know impact impact term pharmacokinetics drugdrug interaction either raltegravir , dolutegravir , maraviroc . This include : Inducers UGT1A1 ( rifampin , phenytoin , phenobarbital rifabutin , St. John 's wort ) Cytochrome P3A inhibitor ( ketoconazole , itraconazole , clarithromycin , nefazodone , telithromycin ) Cytochrome P3A inducer ( rifampin , carbamazepine , phenobarbital phenytoin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hepatitis C virus ( HCV )</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>Human immunodeficiency virus ( HCV )</keyword>
</DOC>